EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Tocilizumab in refractory rheumatoid arthritis: long-term efficacy, safety, and tolerability beyond 2 years

Ziad Farah, Sabreen Ali, Fiona Price-Kuehne, Charles G Mackworth-Young

Biologics: Targets and Therapy · 2016

DOI: 10.2147/btt.s101289 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biologics: Targets and Therapy, 2016. Verfasst von Ziad Farah und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Charing Cross Hospital, London, UK. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

efficacylong termrefractory rheumatoidrheumatoid arthritissafetytocilizumabtolerability

Autor:innen und Institutionen

  • Department of Rheumatology, Charing Cross Hospital, London, UK.

Zitieren

APA

Farah, Z., Ali, S., Price-Kuehne, F., & Mackworth-Young, C. G. (2016). Tocilizumab in refractory rheumatoid arthritis: long-term efficacy, safety, and tolerability beyond 2 years. Biologics: Targets and Therapy. https://doi.org/10.2147/btt.s101289

Vancouver

Farah Z, Ali S, Price-Kuehne F, Mackworth-Young CG. Tocilizumab in refractory rheumatoid arthritis: long-term efficacy, safety, and tolerability beyond 2 years. Biologics: Targets and Therapy. 2016. doi:10.2147/btt.s101289

BibTeX
@article{Farah2016,
  author = {Farah, Ziad and Ali, Sabreen and Price-Kuehne, Fiona and Mackworth-Young, Charles G},
  title = {Tocilizumab in refractory rheumatoid arthritis: long-term efficacy, safety, and tolerability beyond 2 years},
  journal = {Biologics: Targets and Therapy},
  year = {2016},
  doi = {10.2147/btt.s101289}
}
Kostenlos starten →